SNY - Sanofi

NYSE - NYSE Delayed Price. Currency in USD
43.43
+0.54 (+1.26%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close42.89
Open43.39
Bid0.00 x 900
Ask0.00 x 1200
Day's Range43.33 - 43.71
52 Week Range37.43 - 50.04
Volume1,094,660
Avg. Volume1,676,352
Market Cap106.886B
Beta (3Y Monthly)0.75
PE Ratio (TTM)26.98
EPS (TTM)1.61
Earnings DateN/A
Forward Dividend & Yield1.86 (4.34%)
Ex-Dividend Date2018-05-09
1y Target Est48.67
Trade prices are not sourced from all markets
  • Trump administration: Drug makers should disclose prices in TV ads
    Yahoo Finance9 hours ago

    Trump administration: Drug makers should disclose prices in TV ads

    just after drug companies announced they will be disclosing prices of drugs advertised on TV via a website, the Trump administration proposes a rule to require medicare and medicaid drugs to disclose price in TV ads.

  • Reuters1 hour ago

    Sanofi, Regeneron say late-stage Dupixent trials show positive results

    Drugmakers Sanofi and Regeneron said on Tuesday that they received positive results for their Dupixent product, which treats eczema and is seen as a key driver of future revenues. Sanofi and Regeneron ...

  • Novartis in Q3 2018: Analysts Expect Revenue Growth
    Market Realist17 hours ago

    Novartis in Q3 2018: Analysts Expect Revenue Growth

    Analysts expect Novartis’s revenues to increase ~4.9% to $13.02 billion in the third quarter of 2018. There has been operating revenue growth for all three of its segments in the quarter. Analysts expect Novartis’s Innovative Medicines segment to report revenue growth in the third quarter of 2018 compared to the third quarter of 2017.

  • An Update on Bausch + Lomb/International in October
    Market Realist19 hours ago

    An Update on Bausch + Lomb/International in October

    Bausch + Lomb/International, a subsidiary of Bausch Health (BHC), generated net revenues of $1.21 billion in the second quarter, compared to $1.22 billion in the second quarter of 2017. This increase reflects ~4.0% YoY (year-over-year) organic growth. 

  • What to Do When You Can't Afford Your Chronic Disease Medication
    PR Newswire5 days ago

    What to Do When You Can't Afford Your Chronic Disease Medication

    BRIDGEWATER, N.J., Oct. 11, 2018 /PRNewswire/ -- If you find yourself spending more on health care than ever, you're not alone. Americans under the age of 65 who were insured through their employer spent more than ever on health care, and spending grew faster in 2016 than in recent years. For some patients, the problem is a lack of health insurance or a sudden gap in coverage that may come with a job change.

  • Analysts’ Estimates and Ratings for Novartis in October
    Market Realist5 days ago

    Analysts’ Estimates and Ratings for Novartis in October

    Novartis’s (NVS) revenue is mainly driven by the strong performance of its Innovative Medicines segment, while Sandoz and Alcon also contribute to the company’s overall growth.

  • A Look at the Performance of Novartis’s Alcon
    Market Realist5 days ago

    A Look at the Performance of Novartis’s Alcon

    Alcon reported revenue of ~$1.82 billion in the second quarter, a 7% rise including the 5% increase in its operating revenue and the 2% favorable impact of foreign exchange. Alcon announced in September 2018 that it would be locating its future headquarters in Geneva, Switzerland, following the completion of the proposed spinoff from Novartis.

  • A Closer Look at Novartis’s Innovative Medicines Segment
    Market Realist6 days ago

    A Closer Look at Novartis’s Innovative Medicines Segment

    Novartis’s (NVS) Innovative Medicines segment includes prescription products from two business units: Novartis Pharmaceuticals and Novartis Oncology.

  • How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support
    Investor's Business Daily7 days ago

    How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support

    The concept of support is not one of the first things you need to understand as an investor, but you will find it a powerful tool once you learn to use it.

  • Keeping Women In STEM Careers: Looking to Data For Answers
    PR Newswire7 days ago

    Keeping Women In STEM Careers: Looking to Data For Answers

    BRIDGEWATER, N.J., Oct. 9, 2018 /PRNewswire/ -- Companies across industries from IT to biopharma have long emphasized the importance of recruiting and maintaining women in jobs in the so-called STEM fields – Science, Technology, Engineering, and Math. "We know from our own experience, and demonstrated by research, that gender diversity creates greater value, and that an inclusive culture is far more likely to be innovative and agile," says Cristina Santos, Sanofi's Head of Inclusion & Diversity and EEO North America. More than half of the highly qualified women in STEM jobs will eventually quit because of factors like lack of opportunity, bias, or isolation by male peers.

  • InvestorPlace8 days ago

    Vaxart’s Flu Vaccine Looks Promising, But Its Future Is Uncertain

    Just look at biotech company Vaxart (NASDAQ:VXRT), whose shares soared by a sizzling 78% to $5.25. Of course, the company got some favorable news from one of its clinical trials. In a Phase 2 study, patients taking its H1 influenza vaccine showed a 39% reduction in illness compared to those taking a placebo.

  • How Much Upside Potential Do Analysts See in JNJ Stock?
    Market Realist8 days ago

    How Much Upside Potential Do Analysts See in JNJ Stock?

    Johnson & Johnson (JNJ) has a market capitalization of $373.8 billion. Although the company has had several litigation issues in recent years, it has registered strong quarterly results and has had some key launches and approvals.

  • Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
    Zacks11 days ago

    Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up

    Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.

  • Sangamo Therapeutics: Analysts Expect 88% Upside Potential
    Market Realist11 days ago

    Sangamo Therapeutics: Analysts Expect 88% Upside Potential

    Sangamo Therapeutics (SGMO), a clinical stage biotechnology firm, is focused on developing gene-based therapies using industry-leading technology platforms in gene therapy, cell therapy, genome editing, and gene regulation. The company has collaborations with a number of leading pharmaceuticals firms including Gilead Sciences (GILD), Sanofi (SNY), and Pfizer (PFE) to develop a wide range of genomic therapies. In this part, we’ll discuss Sangamo Therapeutics’ recent recommendations and target prices from Wall Street analysts.